Zealand Pharma expands management team
Danish biopharmaceutical firm makes three senior appointments
"Together they bring a wealth of experience, energy and skills to Zealand Pharma as we continue to advance our growth strategy," said David Horn Solomon, chief executive of Zealand Pharma.
Grondahl starts on 1 April, joining the firm from Novo Nordisk, where until recently he was corporate vice president for strategic alliances.
Blom, who joined the company earlier this month, was cfo of Swedish Orphan International, which recently merged with Biovitrum to form Swedish Orphan-Biovitrum of Stockholm.
Hyttel, who became senior vice president for operations on 1 March, founded Zealand Pharma in 1998. He worked for H Lundbeck for 30 years prior to joining Zealand.
Zealand's most advanced project, Lixisenatide (ZP10/AVE0010), a GLP-1 agonist for the treatment of Type II diabetes has been out licensed to Sanofi-Aventis of France. Sanofi-Aventis is completing 9 Phase III trials with first results to be released in June. Sanofi-Aventis is also commercialising a Lantus-Lixisenatide combination product for the treatment of Type II diabetes that has completed Phase I clinical studies. Submission of IND/MAA for Lixisenatide is expected in 2011.
You may also like
Regulatory
NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Research & Development
Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions
Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster